NextCure (NXTC) Competitors $5.58 +0.03 (+0.52%) Closing price 03:58 PM EasternExtended Trading$5.57 -0.01 (-0.16%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. CUE, ALXO, KPTI, NRXP, PDSB, DTIL, ELUT, GNTA, ICCC, and INMBShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Cue Biopharma (CUE), ALX Oncology (ALXO), Karyopharm Therapeutics (KPTI), NRx Pharmaceuticals (NRXP), PDS Biotechnology (PDSB), Precision BioSciences (DTIL), Elutia (ELUT), Genenta Science (GNTA), ImmuCell (ICCC), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Cue Biopharma ALX Oncology Karyopharm Therapeutics NRx Pharmaceuticals PDS Biotechnology Precision BioSciences Elutia Genenta Science ImmuCell INmune Bio Cue Biopharma (NASDAQ:CUE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment. Is CUE or NXTC more profitable? NextCure has a net margin of 0.00% compared to Cue Biopharma's net margin of -469.35%. NextCure's return on equity of -106.62% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-469.35% -230.13% -111.16% NextCure N/A -106.62%-85.20% Do analysts recommend CUE or NXTC? NextCure has a consensus target price of $25.50, indicating a potential upside of 357.07%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer CUE or NXTC? In the previous week, NextCure had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Cue Biopharma. NextCure's average media sentiment score of 0.38 beat Cue Biopharma's score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Overall Sentiment Cue Biopharma Neutral NextCure Neutral Which has stronger earnings and valuation, CUE or NXTC? Cue Biopharma has higher revenue and earnings than NextCure. Cue Biopharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M6.04-$40.67M-$0.56-1.30NextCureN/AN/A-$55.65M-$25.82-0.22 Do insiders & institutionals hold more shares of CUE or NXTC? 35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by company insiders. Comparatively, 17.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, CUE or NXTC? Cue Biopharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, NextCure has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. SummaryNextCure beats Cue Biopharma on 11 of the 15 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.95M$3.14B$5.81B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-0.2221.3676.9327.00Price / SalesN/A249.24449.2788.58Price / CashN/A45.4837.2260.63Price / Book0.209.6913.836.37Net Income-$55.65M-$52.92M$3.29B$271.46M7 Day Performance2.56%1.44%0.93%2.35%1 Month Performance6.06%6.03%5.31%7.78%1 Year Performance-66.79%12.89%84.25%32.27% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.634 of 5 stars$5.58+0.5%$25.50+357.1%-66.5%$14.95MN/A-0.2290Short Interest ↓CUECue Biopharma1.6043 of 5 stars$0.74-0.2%N/A+26.7%$56.98M$8.29M-1.3260ALXOALX Oncology3.7449 of 5 stars$1.05-0.9%$3.30+214.3%-51.8%$56.76MN/A-0.4840News CoverageKPTIKaryopharm Therapeutics3.7286 of 5 stars$6.26-2.9%$34.00+443.1%-46.0%$55.93M$145.24M-0.43380NRXPNRx Pharmaceuticals3.3809 of 5 stars$3.00+7.1%$34.50+1,050.0%+78.0%$55.47MN/A-1.342Positive NewsPDSBPDS Biotechnology1.6744 of 5 stars$1.16flat$10.00+762.1%-63.1%$54.55MN/A-1.2620News CoveragePositive NewsDTILPrecision BioSciences4.1295 of 5 stars$4.50-2.4%$47.00+944.4%-55.7%$54.34M$1.26M-0.51200ELUTElutia3.1355 of 5 stars$1.22-4.7%$7.00+473.8%-72.5%$54.27M$23.68M-1.15180Gap UpGNTAGenenta Science2.6127 of 5 stars$3.06+3.6%$25.00+718.1%-4.8%$53.96MN/A0.007Positive NewsICCCImmuCell1.075 of 5 stars$5.95+0.5%N/A+52.3%$53.55M$26.49M31.3270Gap DownHigh Trading VolumeINMBINmune Bio3.5013 of 5 stars$1.97-2.0%$18.40+834.0%-65.6%$53.44M$50K-0.7910News CoveragePositive NewsShort Interest ↓High Trading Volume Related Companies and Tools Related Companies CUE Competitors ALXO Competitors KPTI Competitors NRXP Competitors PDSB Competitors DTIL Competitors ELUT Competitors GNTA Competitors ICCC Competitors INMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
